Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

ByMarketFacts

Y-mAbs Therapeutics Inc. (XNAS: YMAB), incorporated in 2015 and headquartered in New York is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.

The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA, which targets tumors that express GD2, and one product candidate at the registration stage, OMBLASTYS, which targets tumors that express B7-H3.

Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

ByMarketFacts

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

What Is Equity Research and Why Is It Important?

What Is Equity Research and Why Is It Important?

ByMarketFacts

There are many uncertainties surrounding the stock market, so investing in stocks has always been seen as a gamble. It is a common misconception in the stock market that success depends entirely on chance. A miracle may bring instant riches; a catastrophe may ruin all your hard work.

Everything is true to an extent, but equity research comes into play to protect people from the uncertainties of the stock market. Equity research acts as a timely and effective shield, ensuring the protection of investors.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

ByMarketFacts

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

How to survive bear market ?

How to survive bear market ?

ByMarketFacts

As reflected in the Standard & Poor’s 500 and the Nasdaq Composite Index, a Bear Market is commonly defined as a stock market decline of 20% or more from its recent highs. Factors such as weak or declining economy, pandemics, wars, interest rate hikes, oil price movements, bursting market bubbles and unexpected high inflation figures can all contribute to a bear market.  

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?

ByMarketFacts

Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.

How The Fed’s Interest Rate Hike Affect Your Money

How The Fed’s Interest Rate Hike Affect Your Money

ByMarketFacts

The Federal Reserve’s goal is to maintain a healthy economic climate in the United States. Disturbances like inflation and asset bubbles may get out of hand and undermine economic stability when the economy is booming and running hot.

When inflation threatens to spiral out of control, the Federal Reserve typically responds by raising interest rates to restore stability and slow inflation. This year the federal funds rate set by the Federal Reserve has been a hot topic of discussion and rightly so.

Is ESI a good opportunity for investors seeking growth: Element Solutions Inc (NYSE: ESI)?

Is ESI a good opportunity for investors seeking growth: Element Solutions Inc (NYSE: ESI)?

ByMarketFacts

Element Solutions Inc. (XYNS: ESI) is a global diversified specialty chemicals company focused on providing innovative solutions across several large and growing end-markets that enhance the products of everyday life. Developed in multi-step technological processes, the company’s innovative solutions enable the customers’ manufacturing processes in several key segments, including electronic circuitry, communication infrastructure, automotive systems, industrial surface finishing, consumer packaging, and offshore energy. With a long-standing presence in automotive markets and a deep market expertise in electronics, it sits at the intersection of this fast-growing market.

Should you buy the dip now as growth resumes in Alteryx Inc (NYSE: AYX)?

Should you buy the dip now as growth resumes in Alteryx Inc (NYSE: AYX)?

ByMarketFacts

Alteryx Inc. (NYSE: AYX) is a software company that offers self-service data analytics software. By using its software platform, businesses may boost business results and business analyst productivity by significant margins. The company provides a wide range of services, including advanced analytics, location intelligence, data preparation, technological integrations, and more. Its customer base includes businesses in the financial, healthcare, retail, logistics, oil & gas, pharmaceutical, and biotech sectors. The primary source of income for the business is the licensing of its software platform to users on a subscription basis.

Top 5 Healthcare Stocks Expected To Thrive Post Pandemic

Top 5 Healthcare Stocks Expected To Thrive Post Pandemic

ByMarketFacts

Healthcare has become one of the world’s largest sector, both in terms of revenue and employment. It comprises of hospitals, medical devices, equipment, insurance, medicines, and vaccines. The US healthcare industry is massive, with healthcare spending accounting for over 19.7% of US GDP in 2020. As a result, the healthcare sector in US is seeing strong and sustained growth.
Since the demand for healthcare products is ever increasing, the sector provides steady and consistent returns that are uncorrelated with the overall direction of the stock market. Here are the top 5 healthcare stocks to look out for.